KCG Holdings Inc. purchased a new stake in Rockwell Medical, Inc. (NASDAQ:RMTI) during the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 17,671 shares of the company’s stock, valued at approximately $111,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of RMTI. Geode Capital Management LLC boosted its position in Rockwell Medical by 9.7% in the first quarter. Geode Capital Management LLC now owns 371,700 shares of the company’s stock valued at $2,326,000 after buying an additional 32,964 shares in the last quarter. Vanguard Group Inc. boosted its position in Rockwell Medical by 4.9% in the first quarter. Vanguard Group Inc. now owns 1,990,057 shares of the company’s stock valued at $12,458,000 after buying an additional 93,589 shares in the last quarter. American International Group Inc. boosted its position in Rockwell Medical by 7.1% in the first quarter. American International Group Inc. now owns 29,509 shares of the company’s stock valued at $185,000 after buying an additional 1,955 shares in the last quarter. Balasa Dinverno & Foltz LLC boosted its position in Rockwell Medical by 6.2% in the first quarter. Balasa Dinverno & Foltz LLC now owns 51,300 shares of the company’s stock valued at $321,000 after buying an additional 3,000 shares in the last quarter. Finally, Geneva Advisors LLC boosted its position in Rockwell Medical by 3.7% in the first quarter. Geneva Advisors LLC now owns 20,970 shares of the company’s stock valued at $131,000 after buying an additional 750 shares in the last quarter. 20.54% of the stock is owned by hedge funds and other institutional investors.
Shares of Rockwell Medical, Inc. (RMTI) remained flat at $6.37 on Friday. The stock had a trading volume of 23,611 shares. The firm has a 50 day moving average price of $7.46 and a 200 day moving average price of $6.88. Rockwell Medical, Inc. has a 52 week low of $3.55 and a 52 week high of $8.98. The company’s market cap is $329.58 million.
Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by $0.04. The business had revenue of $13.24 million during the quarter, compared to analyst estimates of $13.05 million. Rockwell Medical had a negative return on equity of 40.38% and a negative net margin of 39.68%. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.11) EPS. On average, analysts predict that Rockwell Medical, Inc. will post ($0.43) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “KCG Holdings Inc. Purchases New Stake in Rockwell Medical, Inc. (RMTI)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.com-unik.info/2017/08/11/kcg-holdings-inc-purchases-new-stake-in-rockwell-medical-inc-rmti.html.
Several research analysts recently issued reports on the stock. BidaskClub raised shares of Rockwell Medical from a “strong sell” rating to a “sell” rating in a report on Friday. Zacks Investment Research upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, ValuEngine lowered shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research report on Friday, June 2nd. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $7.50.
About Rockwell Medical
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
What are top analysts saying about Rockwell Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Rockwell Medical Inc. and related companies.